Background: Approximately 30% of older adults have disrupted gait. It is associated with increased risk of cognitive decline, disability, dementia, and death. Additionally, most older adults present with 1 or more neuropathologies at autopsy. Recently, there has been an effort to investigate the association between subclinical neuropathology and gait. Summary: We reviewed studies that investigated the association between gait and neuropathologies. Although all pathologies reviewed were associated with gait, grey matter atrophy was most consistently linked with poorer gait performance. Studies investigating the association between white matter and gait focused primarily on total white matter. Future research using more parsed regional analysis will provide more insight into this relationship. Evidence from studies investigating neuronal activity and gait suggests that gait disruption is associated with both under-and overactivation. Additional research is needed to delineate these conflicting results. Lastly, early evidence suggests that both amyloid and tau aggregation negatively impact multiple gait parameters, but additional studies are warranted. Overall, there was substantial methodological heterogeneity and a paucity of longitudinal studies. Key Messages: Longitudinal studies mapping changes in different types of neuropathology as they relate to changes in multiple gait parameters are needed to better understand trajectories of pathology and gait.
Introduction
Gait abnormalities affect approximately 30% of older adults [1] . Gait decline is associated with an increased risk of functional and cognitive decline, disability, dementia, and death [2, 3] . Gait parameters can be classified into 3 categories: spatial (e.g., stride length), temporal Titles were screened for keywords. Abstracts were screened if titles were insufficient. We excluded studies from review if they were conducted in samples of patients with significant medical conditions (e.g., Down syndrome, HD, PD, Creutzfeldt-Jakob), investigated cerebrovascular pathologies, or did not meet our other criteria (i.e., not conducted in humans, only examined falls as an outcome). We included studies for review if they measured both gait and neuropathology either via imaging methods, on autopsy, or in cerebrospinal fluid (CSF) in middle-to older-aged adults. Additional studies were identified from the reference sections of selected papers.
We included 31 studies, 23 of which measured brain volume or tissue integrity and gait, 3 that assessed glucose uptake, 4 that measured Aβ, and 1 that assessed tau. These studies are summarized in Tables 1-4 . Although the methods of these studies were too heterogeneous to complete a meta-analysis, we did summarize the findings by regions of interest (ROI) ( Tables 5 and 6 ). All studies reviewed met quality guidelines set forth by the National Institutes of Health [16] .
White Matter
Studies that have investigated the association between WM atrophy and gait have focused mostly on total WM, as measured by structural magnetic resonance imaging (MRI). One crosssectional study found, among 112 nondemented community-dwelling adults aged 70 years and older, that greater bilateral total WM was associated with faster gait speed ( Table 1 ) . However, this association was not significant after excluding participants with mild cognitive impairment (MCI) [17] . Longitudinally, one study of 225 community-dwelling older adults (mean age = 71) without severe gait impediments or contraindication to MRI reported that change in total WM atrophy was associated with declining gait speed, step length, and cadence over an average of 30 months [18] .
Using diffusion tensor imaging techniques, researchers have investigated the association between WM integrity and gait. A study among high-functioning older adults (mean age = 83) found that global greater mean diffusivity (MD) was associated with greater step length variability [19] . Additionally, in 173 community-dwelling older adults (mean age = 73), lower Slower maximum gait speed and lower cadence at maximum gait speed was associated with lower glucose uptake in the PFC, posterior cingulate, and parietal cortices LSV, low step variability; HSV, high step variability; PFC, prefrontal cortex.
fractional anisotropy (FA), indicating less WM microstructural integrity, in the genu, but not the splenium of the corpus callosum, was associated with poorer gait and balance [20] . Importantly, this association was independent of WMH volume. In CN older adults (mean age = 71), lower FA in the left anterior thalamic radiation and left corticospinal tract was associated with reduced step width and greater instability measured during treadmill walking [21] . The corpus callosum is primarily responsible for communication across hemispheres, and the genu primarily connects the left and right prefrontal and anterior frontal cortices [22] . Together, these findings support the idea that integrity of the frontal areas associated with executive function is important for gait and balance, and that gait and balance involve the coordination of multiple areas across hemispheres. The association between WM integrity within the context of substantial cerebrovascular burden has also been examined. Among 429 nondemented later middle-aged adults (mean age = 65) with cerebral small vessel disease, lower FA and higher MD of the corpus callosum was associated with slower gait speed, reduced stride length and cadence, and increased stride width [23] . In a smaller study of 20 older adults (range = 65-84) with significant cerebrovascular pathology, lower FA and higher MD, and axial and radial diffusivity across all WM were associated with freezing of gait [24] . Another study that examined the effect of FA within the context of WMHs found that FA measures throughout WM regions significantly moderated the association between WMH volume and gait speed among 265 community-dwelling older adults (mean age = 83) [25] . Specifically, among those with high FA, there was no association between WMH and gait speed. These results suggest that WMHs alone may not be associated with slower gait and are consistent with the hypothesis that the interaction between multiple pathologies is necessary to substantially affect gait performance [26] . In summary, the evidence presented here suggests that WM atrophy is associated with disrupted gait; however, it is not overwhelmingly compelling, particularly compared to the association between other types of pathology and gait (e.g., GM atrophy), as described below. The few studies investigating the association between gait and WM volume have focused on total volume [17, 18] . This broad type of investigation may be obscuring regional differences. It may be that more parsed analyses investigating individual regions are needed to detect a stronger association between WM and gait. [62, 63] investigated the association between AD pathology (neuritic plaques, diffuse plaques, and neurofibrillary tangles) averaged across midfrontal, superior temporal, inferior parietal, entorhinal, and hippocampal ROIs and gait, so it was not possible to differentiate by ROI or pathology type in these instances.
Ventricles
Ventricular enlargement may be indicative of GM atrophy, declines in CSF reabsorption, and/or total generalized brain atrophy. Among 20 community-dwelling MCI patients (mean age = 76), greater left ventricular volume of both the main bodies and temporal horn was associated with slower gait speed [27] ( Table 1 ) . Further, bilateral larger temporal horns were associated with greater stride-to-stride variability among 115 community-dwelling older adults (mean age = 70 years) [28] . Similarly, among 321 CN and MCI subjects, slower gait speed was associated with severe ventricular enlargement (i.e., ventricular grade >5) [29] . Ventricular enlargement is a nonspecific measure of cerebral damage, which could explain why the association with gait impairment was only observed with severe ventricular enlargement.
Grey Matter
GM volume decreases with age, and this decrease is further exacerbated in aging-related diseases such as type 2 diabetes and AD [30] [31] [32] . The associations between spatial, temporal, and spatiotemporal gait parameters and reduced cortical thickness have been widespread across cortical regions. Six studies reported that lower total GM volume was associated with poorer performance on multiple gait measures [17, 19, [33] [34] [35] [36] ( Table 1 ) . Seven studies showed that smaller GM volume in frontal regions was associated with poorer gait [33, 34, [37] [38] [39] [40] [41] . Five studies showed a relationship between lower GM volume in the parietal lobe and poorer performance on gait parameters [33, [37] [38] [39] [40] . Four studies found that lower GM volume in temporal lobe regions [37, 38, 42, 43] , cerebellum [37, 40, 43, 44] and basal ganglia, insula, and limbic systems [33, 37, 38, 40] was associated with disrupted gait. Three studies found that smaller GM volume in motor areas [33, 38, 39] and the hippocampus were also associated with poorer gait performance [17, 18, 45] .
Across all ROIs reviewed, the association between GM volume in frontal regions and gait was the most commonly reported. This finding supports the hypothesis that gait involves regions important for higher-level cognitive functioning. Indeed, decline in prefrontal ROIs is [62, 63] investigated the association between AD pathology (neuritic plaques, diffuse plaques, and neurofibrillary tangles) averaged across midfrontal, superior temporal, inferior parietal, entorhinal, and hippocampal ROIs and gait, so it was not possible to differentiate by ROI or pathology type in these instances. associated with executive dysfunction [46] . The strong relationship reported between the parietal lobe and gait is also not surprising because parietal regions are central to sensory integration, visuospatial function, and managing the relationship between one's self and surroundings [39, 40, 47] . Findings that the caudate nucleus is associated with gait are supported from research in PD and HD, which are both characterized by disrupted gait and marked caudate nucleus atrophy [48, 49] . The association between widespread GM atrophy and gait supports the theory that the coordination and interaction of multiple brain regions is necessary for proper gait performance.
The association with GM volume within the context of cerebrovascular pathology has also been examined. De Laat et al. [33] studied the association between cortical thickness and gait within the context of small vessel disease. Among 415 community-dwelling adults (age range 50-85 years) with cerebral small vessel disease, disrupted gait (i.e., slower gait speed, shorter stride length, lower cadence, wider stride width) was associated with lower GM volume across the cortex, including frontal, orbitofrontal, ventrolateral prefrontal, inferior parietal, visual, primary motor and premotor, temporal and left fusiform gyri, visual areas, insula, and cingulate ROIs. Similarly, Smith et al. [34] found that smaller total GM volume, in the context of cerebral small vessel disease, was associated with slower TUG. These findings suggest that even in the context of small vessel disease, widespread GM atrophy in areas associated with cognition and visuospatial processing is associated with disrupted gait.
Additionally, the relationship between GM volume and gait has been explored specifically in MCI. In a smaller study ( n = 20) of MCI patients, thinner motor cortex measures were associated with slower gait speed in both single and dual task walking, and greater stride time variability during single task walking [50] . Another study examined the association between both GM and WM volumes and mobility in 170 older adults diagnosed as CN, amnestic MCI (aMCI), or nonamnestic MCI (naMCI) [35] . Participants completed both the real TUG (rTUG) and imagined TUG (iTUG). Smaller total GM volume was associated with slower rTUG, and smaller total and left PFC volume was associated with slower iTUG. The strongest association between brain volume and TUG performance was seen in the naMCI group. This may suggest that the pathological changes occurring in naMCI affects motor imagery, and this is independent of the kinesthetic completion of motor tasks (e.g., rTUG).
GM volume has also been associated with more severe measures of motor dysfunction (bradykinesia and gait disturbance), which is prevalent even among older adults without neurological conditions [42, 51, 52] . Among 307 community-dwelling older adults (mean age = 83) without PD, smaller GM sensorimotor cortical and posterior parietal lobe volumes were associated with bradykinesia and gait disturbance. Smaller GM medial temporal lobe volume was associated only with gait disturbance and smaller GM volume in the cerebellum, and dorsolateral prefrontal cortex (dLPFC) was associated only with bradykinesia [43] .
Together, the above studies suggest that there is a strong association between GM atrophy and gait. However, there is a paucity of longitudinal evidence, so it is difficult to determine trajectories of atrophy and gait. Indeed, only 1 study [18] examined the association between GM and gait over time. Future studies are also needed to systematically examine specific ROIs and consistently measure multiple gait parameters to elucidate whether GM atrophy in certain ROIs is more or less associated with different gait parameters.
Neuronal Activity
Glucose uptake is a measure of neuronal activity, and has been shown to decrease in normal aging, with further decline in dementia [53] [54] [55] . Greater glucose uptake is indicative of neuronal activation or upregulation, whereas reduced glucose uptake is indicative of deac-tivation or downregulation. Based on findings from functional MRI studies, Jahn et al. [56, 57] proposed a supraspinal locomotor network that includes the frontal cortex, basal ganglia, brain stem tegmentum, and cerebellum. This network, which is activated during locomotion across species and can be interrupted by lesions, provides insight into the locomotive process. Their locomotor network hypothesis is supported by findings from a study that examined glucose uptake measured by with fludeoxyglucose ( Table 2 ). The greatest uptake was in the bilateral central region, particularly focused in the mesial part of the primary cortex, the primary somatosensory cortex, lingual gyrus, fusiform gyrus, and parahippocampal gyrus during walking. Additionally, the authors observed greater uptake in the occipital lobe and precuneus. The first group of brain areas is associated with visually guided navigation, while the latter areas are associated with visual-motor coordination.
A study that measured glucose uptake in 24 community-dwelling women aged 75-82 years similarly found greater glucose uptake in the occipital lobe, as well as the sensorimotor area and cerebellum during treadmill walking [59] . Their results showed reduced uptake in the orbitofrontal and superior frontal gyrus, dLPFC, supplementary motor area, middle and superior temporal gyrus, posterior cingulate cortex, pons, and hippocampus. Another study separated participants into low step variability (LSV) and high step variability (HSV) groups, because, as aforementioned, greater step variability is associated with increased risk of negative clinical outcomes [4, 5] . The LSV group showed greater sensorimotor activation than the HSV group. Additionally, the HSV group had relative deactivation of the supplementary motor area, dLPFC, and hippocampus during treadmill walking. The authors hypothesized that deactivation, as assessed by lower glucose uptake, of the supplementary motor area and dLPFC in the HSV group indicate that these participants found it more difficult to adapt to the novel walking environment (i.e., the treadmill). The observed greater activation of the hippocampus is in line with earlier findings [60] , indicating that hippocampal metabolism and atrophy are associated with greater step length variability. In contrast, lower glucose uptake in the prefrontal, posterior cingulate, and parietal cortices was associated with slower maximum walking speed and lower cadence at maximum walking speed among 182 community-dwelling women aged 55-89 years [61] . This finding indicates that lower neural activation, as opposed to increased neural activation, is associated with poorer gait.
Associations between gait and cerebral glucose uptake are diffuse across brain regions, including frontal, temporal, parietal, and occipital lobes, and the cerebellum and limbic areas. This is consistent with the hypothesis put forth by Jahn et al. [56, 57] , indicating that locomotion requires coordination of multiple brain regions, including those involved in higher-level cognition. It is unclear, however, whether higher glucose uptake (which suggests upregulation and recruitment of brain regions) is needed to execute gait, or lower glucose uptake (which suggests cerebral dysfunction) is associated with gait. For example, the study from Shimada et al. [59] found HSV participants had lower glucose uptake in sensorimotor areas, but higher glucose uptake in the hippocampus. It may be that different brain regions respond contrarily to the demands of gait functioning, and therefore have varying glucose uptake patterns. Longitudinal studies will be critical for understanding these associations to determine whether decreased and/or increased glucose uptake, perhaps dependent on the ROI, predicts gait decline.
Amyloid Beta
Over 30% of adults over the age of 70 have substantial cerebral Aβ deposition [13] . However, few studies have investigated the association between Aβ and gait. Two autopsy studies reported that greater AD pathology (neuritic plaques, diffuse plaques, and neurofi-brillary tangles) deposition in the midfrontal, superior temporal, inferior parietal, entorhinal cortices, and hippocampus was associated with reduced gait speed prior to death and declining gait speed up to 6 years prior to death [62, 63] ( Table 3 ) . A study in 128 nondemented older adults (aged 70 years or older) found that greater Aβ deposition in the putamen, caudate, precuneus, and occipital, temporal, and parietal lobes was associated with slower gait speed [64] . The association was strongest for Aβ deposition in the posterior putamen. Given its proximity to the motor corticostriatal circuits, this finding suggests that Aβ deposition contributes to gait dysfunction.
Expanding on this study, we investigated the association between C 11 Pittsburgh Compound B (PiB) [65] PET standardized uptake volume ration (SUVR) and gait parameters in CN adults aged 50-69 [66] . Greater PiB-PET SUVR across ROIs (prefrontal, orbitofrontal, temporal, parietal, anterior and posterior cingulate, and motor) was associated with slower gait speed, lower cadence, longer double support time, and greater stance time variability, independent of neurodegeneration, as measured by FDG-PET and MRI, in AD-signature regions. In sex-stratified analyses, these associations were only significant among women. In conclusion, despite the relatively few studies that have investigated the association between Aβ and gait, it appears that greater Aβ burden is associated with disrupted gait. Longitudinal studies are needed to determine the trajectories between amyloidosis and gait.
Tau
Aggregates of tau protein are part of the pathological process of a number of diseases, including AD and frontotemporal dementia. The majority of research examining the association between gait and tau has been conducted in AD and normal pressure hydrocephalus (NPH) patients [67] [68] [69] . However, one study among 86 participants without PD (or AD or NPH) reported that the number of neurofibrillary tangles in the substantia nigra was significantly associated with declining gait in annual exams prior to death [70] . This evidence suggests that gait and mobility are impacted by tau aggregation both in diagnosed and prodromal disease. With the new availability of tau-PET ligands, imaging will provide information on whether regional deposition of cerebral tau affects gait in vivo, which cannot currently be ascertained by measuring tau in the CSF.
Summary of the Reported Brain Regions Associated with Gait
Pathologies in 3 regions were most often found to be associated with disrupted gait: the frontal regions were associated with gait in 12 studies, and the limbic system and parietal regions, were each associated with gait in 11 studies ( Tables 5 and 6 ). Although there was not strong evidence for the association between the motor cortices and gait, the motor cortex and somatosensory motor cortex are located in the frontal and parietal lobes, respectively, and are a juncture of the inputs from multiple converging cortical and subcortical regions, such as the frontal lobe and thalamus. Further, the motor areas provide input to the descending corticospinal tract [50, 71] . The observed association of the limbic system with gait further suggests that cognition, especially memory, is important for gait. Indeed, past studies have suggested that gait requires memory, particularly in novel situations [35, 45, 59, 60] . Thus, other regions associated with gait and cognitive functioning (e.g., frontal and parietal regions) may impact gait partially through cognitive dysfunction. For additional information, the association between cognition and gait has been reviewed elsewhere [72] .
Gaps in the Literature and Future Directions
Future studies should consider potential sex differences in the association between neuropathologies and gait. Past studies have shown that this relationship can differ between men and women [66] . This is unsurprising given the increased recognition of sex differences in aging [73, 74] , gait changes [73, [75] [76] [77] [78] , and brain and neuropathological development [50, [79] [80] [81] [82] [83] [84] [85] . An empirical understanding of sexual dimorphism across pathologies is important. Reasonably, these differences in pathology would translate to differing patterns of gait dysfunction. Thus, future research should attempt to delineate how different pathologies affect different gait parameters by sex. This may translate into sex-specific clinical guidelines for gait impairment associated with brain pathology. Moreover, most studies in this review investigated the association between a particular pathology and gait speed. However, it is important to examine other gait parameters to determine whether they are differentially affected by specific pathologies, show different trajectories of decline, or have sex-specific differences.
Perhaps the most glaring gap in the literature is the lack of longitudinal studies. Of the research we reviewed, only 2 studies [18, 63] had a longitudinal design. Longitudinal studies are needed to determine how gait trajectories are affected by changes in neuropathology over time. Quantifying trajectories of pathology, based on both type and location, with gait decline will allow for a more precise approach to utilizing gait as a measure in clinic and for therapeutic and intervention trials.
Conclusion
The goal of this review was to summarize research examining the associations between neuropathologies and gait. We found that all pathologies reviewed (i.e., WM, GM, and HVa decline, ventricular enlargement, and amyloid and tau aggregation) were associated with poorer gait performance. The strongest associations were between GM and gait. Regardless, this review further suggests a link between neurodegenerative biomarkers and gait performance.
This review has limitations that should be considered. First, relatively little research has been conducted investigating the association between protein aggregation (i.e., Aβ and tau) and gait, in part because PET ligands have only recently been developed, so it is difficult to draw robust conclusions. However, past reviews have not included these studies, and we hope more research will be conducted investigating the association between protein aggregation and gait. Additionally, we were unable to conduct a meta-analysis due to the heterogeneity of the methods for measuring both neuropathology and gait. For example, some studies used voxel count methods to determine volume while others used ROI methods. These methods produce comparable, but heterogeneous results [86] , and more research is needed to make direct comparisons between these methods [87] . Without a meta-analysis, it is difficult to come to quantitative conclusions about findings in the literature, including determining whether gait parameters were differentially associated with different neuropathologies. Still, we hope this review sheds light on the emerging field of research investigating the link between neuropathologies and gait.
Multiple studies have been published since Rosso et al. [7] put out the call to better understand the connection between the CNS and gait. However, more research is needed to develop a deeper understanding of the link between neurological mechanisms and different facets of gait and mobility [88] . An empirical quantification of the association between neuropathology and gait parameters will contribute to the increased use of gait measures in the clinic and for
